[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"doc-seo-354723-105":3,"detail-sidebar-cat-0-en-105":85,"doc-detail-354723-en":134},{"code":4,"msg":5,"data":6},0,"ok",{"site_id":7,"language":8,"slug":9,"title":10,"keywords":11,"description":12,"schema_data":13,"social_meta":78,"head_meta":80,"extra_data":82,"updated_unix":84},105,"en","pregabalin-enhances-the-proliferative-potential-of-pancreatic-cancer-in-vitro-but-not-in-mice-with-pancreatic-cancer","Pregabalin enhances the proliferative potential of pancreatic cancer in vitro but not in mice with pancreatic cancer","","Background: Prior work showed mirogabalin, a selective α2δ1/α2δ2 ligand, increases pancreatic cancer proliferative potential, but pregabalin risk remains unclear. Methods: Murine KPPC pancreatic cancer was dosed orally with pregabalin or vehicle, and pain, tumor pathology, plasma cytokines, and pancreatic ductal adenocarcinoma cell proliferation were assessed. Results: Pregabalin increased in vitro proliferation yet did not change survival or tumor size, while reducing pain and reshaping inflammatory and immune cell infiltration. Conclusions: Pregabalin enhances in vitro cancer cell proliferation but does not promote in vivo tumor growth.",{"@graph":14,"@context":77},[15,34,56],{"@type":16,"itemListElement":17},"BreadcrumbList",[18,23,27,31],{"item":19,"name":20,"@type":21,"position":22},"https://docshare.wps.com","Home","ListItem",1,{"item":24,"name":25,"@type":21,"position":26},"https://docshare.wps.com/document/","Document",2,{"item":28,"name":29,"@type":21,"position":30},"https://docshare.wps.com/document/research-report/","Research & Report",3,{"item":32,"name":10,"@type":21,"position":33},"https://docshare.wps.com/document/pregabalin-enhances-the-proliferative-potential-of-pancreatic-cancer-in-vitro-but-not-in-mice-with-pancreatic-cancer/354723/",4,{"url":32,"name":10,"@type":35,"image":36,"author":41,"headline":10,"publisher":44,"fileFormat":47,"inLanguage":8,"description":12,"dateModified":48,"datePublished":49,"encodingFormat":47,"isAccessibleForFree":50,"interactionStatistic":51},"DigitalDocument",{"url":37,"@type":38,"width":39,"height":40},"https://docshare.wps.com/thumbnails/pregabalin-enhances-the-proliferative-potential-of-pancreatic-cancer-in-vitro-but-not-in-mice-with-pancreatic-cancer/354723.png","ImageObject",300,407,{"name":42,"@type":43},"CatatanPagi","Person",{"url":19,"name":45,"@type":46},"DocShare","Organization","application/pdf","2026-11-18","2026-09-22",true,{"@type":52,"interactionType":53,"userInteractionCount":55},"InteractionCounter",{"@type":54},"ViewAction",7,{"@type":57,"mainEntity":58},"FAQPage",[59,65,69,73],{"name":60,"@type":61,"acceptedAnswer":62},"What question does the study address about pregabalin and pancreatic cancer?","Question",{"text":63,"@type":64},"It evaluates whether pregabalin affects the proliferative potential of pancreatic cancer similarly to the previously reported effects of mirogabalin, and whether pregabalin changes tumor outcomes in vivo.","Answer",{"name":66,"@type":61,"acceptedAnswer":67},"How was pregabalin administered and what were the key experimental readouts?",{"text":68,"@type":64},"KPPC mouse models received oral pregabalin (30 mg·kg−1·day−1) or vehicle until humane endpoint. Pain scores, tumor pathology, plasma cytokines, and proliferation of pancreatic ductal adenocarcinoma cell lines were measured.",{"name":70,"@type":61,"acceptedAnswer":71},"What were the main in vitro and in vivo findings regarding cancer growth?",{"text":72,"@type":64},"In vitro, pregabalin increased pancreatic cancer cell numbers at 100 and 300 μM. In vivo, pregabalin decreased pain but did not significantly alter survival rate or tumor size.",{"name":74,"@type":61,"acceptedAnswer":75},"How did pregabalin influence immune and inflammatory markers?",{"text":76,"@type":64},"Pregabalin increased local infiltration of CD8+ and CD4+ lymphocytes, natural killer cells, and dendritic cells, while reducing M2-like tumor-associated macrophages and cancer-associated fibroblasts. Plasma cytokines including TNF-α, IL-6, IL-10, IL-13 and several CCLs decreased, while IL-2, IL-15 and several CXCLs increased.","https://schema.org",{"og:url":32,"og:type":79,"og:title":10,"og:site_name":45,"og:description":12},"article",{"robots":81,"canonical":32},"index,follow",{"doc_id":83,"site_id":7},354723,1790211909,{"code":4,"msg":86,"data":87},"success",[88,92,96,100,105,110,114,118,123,126,130],{"id":22,"doc_module":4,"doc_module_name":25,"category_name":89,"show_sort_weight":90,"slug":91},"Story & Novel",90,"story-novel",{"id":26,"doc_module":4,"doc_module_name":25,"category_name":93,"show_sort_weight":94,"slug":95},"Literature",80,"literature",{"id":33,"doc_module":4,"doc_module_name":25,"category_name":97,"show_sort_weight":98,"slug":99},"Exam",70,"exam",{"id":101,"doc_module":4,"doc_module_name":25,"category_name":102,"show_sort_weight":103,"slug":104},5,"Comic",60,"comic",{"id":106,"doc_module":4,"doc_module_name":25,"category_name":107,"show_sort_weight":108,"slug":109},6,"Technology",50,"technology",{"id":55,"doc_module":4,"doc_module_name":25,"category_name":111,"show_sort_weight":112,"slug":113},"Healthcare",40,"healthcare",{"id":115,"doc_module":4,"doc_module_name":25,"category_name":29,"show_sort_weight":116,"slug":117},8,30,"research-report",{"id":119,"doc_module":4,"doc_module_name":25,"category_name":120,"show_sort_weight":121,"slug":122},9,"Religion & Spirituality",20,"religion-spirituality",{"id":121,"doc_module":4,"doc_module_name":25,"category_name":124,"show_sort_weight":121,"slug":125},"World Cup","world-cup",{"id":127,"doc_module":4,"doc_module_name":25,"category_name":128,"show_sort_weight":127,"slug":129},10,"Lifestyle","lifestyle",{"id":131,"doc_module":4,"doc_module_name":25,"category_name":132,"show_sort_weight":101,"slug":133},19,"General","general",{"code":4,"msg":86,"data":135},{"doc_id":83,"user_id":136,"nickname":42,"user_avatar":137,"doc_module":4,"category_id":115,"category_name":29,"doc_title":10,"doc_description":12,"doc_content":138,"file_id":139,"file_url":140,"file_type":141,"file_size":142,"view_count":55,"is_deleted":4,"is_public":22,"is_downloadable":22,"audit_status":22,"page_count":143,"language":144,"language_code":8,"site_id":7,"html_lang":8,"table_of_contents":145,"faqs":146,"seo_title":147,"seo_description":12,"update_tm":148,"read_time":116,"preview_page_count":33,"preview_urls":149},962090894170,"https://ap-avatar.wpscdn.com/davatar_6f874abed73319feea01a86fa6f0fab8","Itaya et al. BMC Pharmacology and Toxicology (2026) 27:121  \n[https://doi.org/10.1186/s40360-026-01176-2](https://doi.org/10.1186/s40360-026-01176-2)  \nBMC Pharmacology and Toxicology  \nRESEARCH Open Access  \nPregabalin enhances the proliferative  potential of pancreatic cancer in vitro but not in mice with pancreatic cancer  \nTomoaki Itaya 1*, Makoto Sano1, Ichie Kajiwara1, Yukino Oshima1, Tomoya Kuramochi2, Jinsuk Kim1, Osamu Kitajima 1, Hideaki Ijichi3,4 and Takahiro Suzuki1  \nAbstract  \nBackground We previously reported that mirogabalin, a selective voltage-gated calcium channel α2δ1/α2δ2 ligand, increases the proliferative potential of pancreatic cancer. However, the risk of pregabalin, a non-selective α2δ ligand, is unknown in pancreatic cancer. Therefore, the proliferation of murine pancreatic cancer cell lines was studied following treatment with pregabalin.  \nMethods Six-week-old pancreatic cancer mouse model KPPC (LSL-KrasG12D/+; Trp53flox/flox; Pdx-1cre/+ ) was orally administrated pregabalin 30 mg · kg−1 · day−1 (n = 10), or vehicle water (n = 14) until the humane endpoint (no activity, food intake of \u003C1 g · day−1 or more than 20% body weight loss within several days) . Cancer-related pain was assessed using the scores ofthe hunching and mouse grimace scale. Tumor status and plasma cytokine levels were determined using histopathological analysis and cytokine antibody arrays, respectively. Proliferative effect of pregabalin was investigated using mouse pancreatic ductal adenocarcinoma cell lines.  \nResults The number of pancreatic cancer cells were increased by 100 and 300 μM pregabalin in vitro. The pain scores in KPPC mice were decreased by pregabalin, but there was no significant difference in the survival rate or tumor size. Interestingly, pregabalin increased the local infiltration of CD8+ and CD4+ lymphocytes, natural killer cells and CD8+ and CD4+ dendritic cells. In contrast, M2-like tumor-associated macrophages and cancer-associated fibroblasts were reduced. Similar to the results of immuno-inflammatory alterations, plasma cytokines such as tumor necrosis factor-α, interleukin (IL)-6, IL-10, IL-13, CC chemokine ligand (CCL)1, CCL2, CCL3, CCL5 and CCL17 decreased, while IL-2, IL-15, CCL19, CCL21, C-X-C motif ligand (CXCL)10, CXCL16 and XCL1 increased by pregabalin.  \nConclusions These findings suggest that pregabalin increases the proliferative ability of pancreatic cancer cells in vitro without promoting tumor growth in vivo. Additionally, it induces an alteration with an increase in tumorinfiltrating lymphocytes and dendritic cells, along with a decrease in M2-like tumor-associated macrophages and cancer-associated fibroblasts in vivo.  \nKeywords Cancer-stromal interaction, Cancer-associated pain, Gabapentin, Pregabalin, Pancreatic ductaladenocarcinoma  \n*Correspondence:  \nTomoaki Itaya [itaya.tomoaki@nihon-u.ac.jp](itaya.tomoaki@nihon-u.ac.jp)  \nFull list of author information is available at the end of the article  \n© The Author(s) 2026. Open Access This article is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License, which permits any non-commercial use, sharing, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if you modified the licensed material. You do not have permission under this licence to share adapted material derived from this article or parts of it. The images or other third party material in this article are included in the article’s Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit [http://creat","cbCaigTbmfEFs2UG","https://ap.wps.com/l/cbCaigTbmfEFs2UG","pdf",4078427,12,"English","# Abstract\n## Background\n## Methods\n## Results\n## Conclusions\n# Introduction\n# Keywords","[{\"question\":\"What question does the study address about pregabalin and pancreatic cancer?\",\"answer\":\"It evaluates whether pregabalin affects the proliferative potential of pancreatic cancer similarly to the previously reported effects of mirogabalin, and whether pregabalin changes tumor outcomes in vivo.\"},{\"question\":\"How was pregabalin administered and what were the key experimental readouts?\",\"answer\":\"KPPC mouse models received oral pregabalin (30 mg·kg−1·day−1) or vehicle until humane endpoint. Pain scores, tumor pathology, plasma cytokines, and proliferation of pancreatic ductal adenocarcinoma cell lines were measured.\"},{\"question\":\"What were the main in vitro and in vivo findings regarding cancer growth?\",\"answer\":\"In vitro, pregabalin increased pancreatic cancer cell numbers at 100 and 300 μM. In vivo, pregabalin decreased pain but did not significantly alter survival rate or tumor size.\"},{\"question\":\"How did pregabalin influence immune and inflammatory markers?\",\"answer\":\"Pregabalin increased local infiltration of CD8+ and CD4+ lymphocytes, natural killer cells, and dendritic cells, while reducing M2-like tumor-associated macrophages and cancer-associated fibroblasts. Plasma cytokines including TNF-α, IL-6, IL-10, IL-13 and several CCLs decreased, while IL-2, IL-15 and several CXCLs increased.\"}]","Pregabalin enhances the proliferative potential of pancreatic cancer in vitro but not in mice with pancreatic cancer | PDF",1790113351,[150,154,158,162],{"page_no":22,"url":151,"width":152,"height":153},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/226257303de7e271355f229815425989.webp",983,1310,{"page_no":26,"url":155,"width":156,"height":157},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/1dbfde596d4fa48d5ffe7ee742f804a8.webp",982,1309,{"page_no":30,"url":159,"width":160,"height":161},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/93bcbb52499f0575f8d2a0c44081c430.webp",981,1308,{"page_no":33,"url":163,"width":164,"height":165},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/34122c90bb4f8fe849f6d42f9c4b1278.webp",980,1306]